Solutions for CTC and TME Immune Evasion
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology provides global collaborators with solutions and related services to study the relationship between tumor microenvironment (TME) and circulating tumor cells (CTCs) and their mechanisms of action, helping them to quickly achieve research goals.
Malignant tumors are increasing in morbidity and mortality worldwide every year, and recurrence and metastasis are the leading causes of poor prognosis. Circulating tumor cells (CTCs) not only have important clinical predictive value, but also may become a therapeutic target to block tumor metastasis. In recent years, it has been found that platelets, natural killer cells (NK), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSC) are among the tumor micro Tumor microenvironment (TME) components may be closely related to the fate of CTCs. Alfa Oncology provides comprehensive services and solutions to study the relationship between tumor microenvironment and immune escape of circulating tumor cells (CTCs) according to your research needs.
An effective screening of key molecules in peripheral blood and tumor microenvironment (TME) that affect the fate of CTCs, such as macrophages, mast cells, neutrophils and exosomes, in addition to the above-mentioned influencing factors, may determine the fate of CTCs and investigate the important mechanisms of their interactions. In addition, based on a clear understanding of the immune escape and survival mechanisms of CTCs, effective interventions targeting the ligands or receptors of key molecules and their signaling pathways can effectively intervene in the occurrence of CTC-mediated metastasis to improve the quality and prolong the survival time of early and postoperative patients.
Alfa Oncology has established a tumor microenvironment technology platform and developed several emerging technologies through which it helps global collaborators to deeply explore the relationship between immune escape of circulating tumor cells (CTC) and TME, hoping to find potential targets for tumor therapy in the process and provide new ideas for clinical anti-tumor treatment.
Single cell sequencing. Alfa Oncology combines efficient cell enrichment methods and advances in molecular biology to perform isolation, enrichment and sequencing of individual circulating tumor cells (CTCs) to elucidate the association between CTC heterogeneity and immune escape. The method of integrating single cell RNA, DNA facilitates the establishment of associations between potential genetic/epigenetic changes and RNA strands.
After entering the circulatory system from the tumor, CTCs face multiple factors, including apoptosis caused by leaving the primary site, shear force of blood flow, and attack by a large number of immune cells. With these factors, only about one in a thousand tumor cells can survive to enter metastasis to distant organs and achieve immune escape. Currently, immunofluorescence, fluorescence quantitative PCR, FISH and other molecular methods are commonly used to identify CTCs by detecting one or some biomarkers, and to investigate the association between CTC immune escape and tumor microenvironment.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.